ASCO26: GLP-1RAs linked with mortality reduction in patients with solid tumours

Several studies of GLP-1RAs in oncology were presented at ASCO 2026, showing their potential in both prevention and treatment. Several studies of GLP-1RAs in oncology were presented at ASCO 2026. GLP-1RAs have shown potential in a number of indications beyond obesity and type 2 diabetes. Credit: Michael Siluk/UCG/Universal Images Group via Getty Images As glucagon-like peptide-1 receptor agonists (GLP-1RA) appear to be taking over the world, research using real-world data (RWD) is showing their potential in oncology beyond their existing benefit in type 2 diabetes and obesity. At the American Society of Clinical Oncology (ASCO) meeting 2026, several studies evaluating…

Source: Clinical Trials Arena